Compare SFWL & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFWL | BNR |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 76.5M |
| IPO Year | 2021 | 2019 |
| Metric | SFWL | BNR |
|---|---|---|
| Price | $0.71 | $11.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.1K | ★ 24.5K |
| Earning Date | 03-27-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $4.75 |
| 52 Week High | $1.29 | $41.72 |
| Indicator | SFWL | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 34.48 | 55.89 |
| Support Level | $0.56 | $8.05 |
| Resistance Level | $1.03 | $13.89 |
| Average True Range (ATR) | 0.09 | 0.93 |
| MACD | -0.02 | 0.66 |
| Stochastic Oscillator | 20.36 | 67.49 |
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The company's operations are based in the PRC. Its integrated logistics solutions are comprised of three business streams: B2B freight transportation services; cloud storage services; and value-added services. The company derives maximum revenue from Transportation, followed by Warehouse storage management services. The solutions provides by the company are : Internet TV; Electronic communication; Textiles and Apparel; Automotive parts; and e-commerce.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.